Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Cancer Vaccines01:30

Cancer Vaccines

503
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
503

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity.

bioRxiv : the preprint server for biology·2024
Same author

BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II.

Cancer immunology research·2022
Same author

Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19.

Journal of the National Cancer Institute·2020
Same author

Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Could BCG be used to protect against COVID-19?

Nature reviews. Urology·2020
Same author

TLR10 Is a B Cell Intrinsic Suppressor of Adaptive Immune Responses.

Journal of immunology (Baltimore, Md. : 1950)·2016
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Sep 5, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

BCG in Bladder Cancer Immunotherapy.

Song Jiang1, Gil Redelman-Sidi2

  • 1Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cancers
|July 9, 2022
PubMed
Summary
This summary is machine-generated.

Bacillus Calmette-Guérin (BCG) immunotherapy is a vital treatment for non-muscle invasive bladder cancer (NMIBC), reducing recurrence and progression. Its precise immune-activating mechanism, involving both innate and adaptive immunity, is still under investigation.

Keywords:
BCGbladderimmunotherapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.3K

Related Experiment Videos

Last Updated: Sep 5, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.3K

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Bacillus Calmette-Guérin (BCG), a live attenuated strain of *Mycobacterium bovis*, is a primary tuberculosis vaccine.
  • BCG has been a cornerstone treatment for non-muscle invasive bladder cancer (NMIBC) for over 40 years.

Purpose of the Study:

  • To review the current understanding of BCG's mechanism of action in NMIBC treatment.
  • To summarize the clinical efficacy, indications, and practical applications of BCG therapy for NMIBC.

Main Methods:

  • Review of existing animal model data.
  • Analysis of human clinical study findings.
  • Synthesis of current literature on BCG's immunological effects and clinical outcomes.

Main Results:

  • BCG immunotherapy demonstrates significant efficacy in reducing tumor recurrence and delaying progression in NMIBC patients.
  • Evidence suggests BCG activates both innate and adaptive immune responses, contributing to tumor cell destruction.
  • The precise immunological pathways are still being elucidated but involve a robust immune system activation.

Conclusions:

  • BCG remains a critical therapeutic option for NMIBC due to its proven clinical benefits.
  • Further research into BCG's mechanism of action can optimize its use and potentially lead to improved treatment strategies.
  • Understanding BCG's immunomodulatory effects is key to its continued success in bladder cancer management.